Drug sales confirm clinical advantage of multi‐target inhibition of drug escapes by anticancer kinase inhibitors-Reference-Cited by-同舟云学术

Drug sales confirm clinical advantage of multi‐target inhibition of drug escapes by anticancer kinase inhibitors

Published:2018-11-13 Issue:2 Volume:80 Page:246-252
ISSN:0272-4391
Container-title:Drug Development Research
language:en
Short-container-title:Drug Dev Res

Author:

Chen Shangying¹,Yang Sheng Yong²,Chen Zhe³,Tan Ying¹,Jiang Yu Yang¹,Chen Yu Zong⁴^ORCID

Affiliation:

1. The State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, Tsinghua University Shenzhen Graduate School, Shenzhen Technology and Engineering Laboratory for Personalized Cancer Diagnostics and TherapeuticsShenzhen Kivita Innovative Drug Discovery Institute Guangdong P. R. China

2. Molecular Medicine Research Center, State Key Laboratory of Biotherapy, West China Hospital, West China School of MedicineSichuan University Chengdu China

3. Zhejiang Key Laboratory of Gastro‐intestinal Pathophysiology, Zhejiang Hospital of Traditional Chinese MedicineZhejiang Chinese Medical University Hangzhou China

4. Bioinformatics and Drug Design Group, Department of PharmacyNational University of Singapore Singapore Singapore

Funder

National NSF of China grant

NSF Project of CQ CSTC grant

Shenzhen Municipal Government grant

NSF Project of CQ CSTC

National NSF of China

Shenzhen Municipal Government

Publisher

Wiley

Subject

Drug Discovery